Results 81 to 90 of about 142,764 (336)

Fibroblast growth factor 20 ameliorates cardiac hypertrophy via activation ErbB2

Heliyon
Fibroblast growth factor 20 (FGF20) is a member of the fibroblast growth factor family and involved in embryonic development and cardiac repair. This study aimed to explore the role of FGF20 in cardiac hypertrophy and the underlying molecular mechanisms.
Yunjie Chen, Xuan Zhou, Xu Wang, Yuanbin Zhang, Jiayi Song, Yan Cai, Yizhuo Zhao, Lin Mei, Suyan Zhu, Xueqin Chen   +9 more
doaj   +1 more source

Synergistic cardiac pathological hypertrophy induced by high-salt diet in IGF-IIRα cardiac-specific transgenic rats.

PLoS ONE, 2019
Stress-induced cardiac hypertrophy leads to heart failure. Our previous studies demonstrate that insulin-like growth factor-II receptor (IGF-IIR) signaling is pivotal to hypertrophy regulation.
Ruey-Lin Chang, Srinivasan Nithiyanantham, Chih-Yang Huang, Pei-Ying Pai, Tung-Ti Chang, Lai-Chin Hu, Ray-Jade Chen, V VijayaPadma, Wei-Wen Kuo, Chih-Yang Huang   +9 more
doaj   +1 more source

Signaling pathways involved in renal oxidative injury: role of the vasoactive peptides and the renal dopaminergic system [PDF]

, 2014
The physiological hydroelectrolytic balance and the redox steady state in the kidney are accomplished by an intricate interaction between signals from extrarenal and intrarenal sources and between antinatriuretic and natriuretic factors.
Choi, Marcelo Roberto, Della Penna, S. L., Fernandez, Belisario Enrique, Kouyoumdzian, Nicolás Martín, Kravetz, Maria Cecilia, Roson, Maria Ines, Rukavina Mikusic, Natalia Lucía   +6 more
core   +3 more sources

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Brain Natriuretic Peptide Production and Secretion in Inflammation

Journal of Transplantation, 2012
Gene expression and secretion of the cardiac polypeptide hormones atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) are simultaneously upregulated in various cardiac disorders such as congestive heart failure, ischemic heart disease ...
Tsuneo Ogawa, Adolfo J. de Bold
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Sudden cardiac death in patients with ischemic heart failure undergoing coronary artery bypass grafting results from the STICH randomized clinical trial (Surgical Treatment for Ischemic Heart Failure) [PDF]

, 2017
Background—The risk of sudden cardiac death (SCD) in patients with heart failure following CABG has not been examined in a contemporary clinical trial of surgical revascularization. This analysis describes the incidence, timing and clinical predictors of
Al-Khatib, Sana M., Carson, Peter E., Cleland, John G.F., Desvigne-Nickens, Patrice M., Feldman, Arthur M., Lang, Irene M., Lee, Kerry L., Nicolau, Jose C., Pokorney, Sean, Rao, Meena P., Romanov, Alexander, Rouleau, Jean L., Selzman, Craig H., She, Lilin, Siepe, Matthias, Stepinska, Janina, Sueta, Carla, Tungsubutra, Wiwun, Velazquez, Eric J., Yii, Michael   +19 more
core   +2 more sources

Discrimination and Quantification of Glomerular Receptor Subtypes for Atrial Natriuretic Factor (Anf) [PDF]

, 1991
Binding sites for atrial natriuretic factor (ANF) were determined on isolated rat glomeruli as well as on glomerular membranes. To define optimal conditions, binding of ANF was investigated varying incubation time, temperature and protein concentration ...
Gerbes, Alexander L., Kollenda, Margit C., Scarborough, Robert M.   +2 more
core   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Doxorubicin Selectively Inhibits Brain versus Atrial Natriuretic Peptide Gene Expression in Cultured Neonatal Rat Myocytes [PDF]

, 1999
Doxorubicin is an antineoplastic agent with significant cardiotoxicity. We examined the effects of this agent on the expression of the natriuretic peptide (NP) genes in cultured neonatal rat atrial myocytes.
Chen, Songcang, Garami, Miklós, Gardner, D. G.   +2 more
core   +1 more source